case_images: PMC10657208_01
case_images: Timeline overview of positive RATs and specimen collection. A visual representation of both the subject testimony in regards to the history of positive RATs and sample collection (Blood, RATs) as part of this case report. Red vertical bars represent the four weeks where we documented positive RAT for this case report, and where the subject provided saliva samples.
case_images: fpubh-11-1240308-g001.jpg
case_images: PMC10657208_01_fpubh-11-1240308-g001.jpg
case_images: fig1
case_images: For the first week, a RAT from another supplier was also performed simultaneously (Figure 1).
case_images: Weekly results of RAT by swabbing technique and location. (A) An overview of the RATs by swabbing technique for week 4 from photographed RAT performed at home. As described, the nasal cavity was swabbed (deep and anterior nasal swab), the oral cavity (throat and cheeks) as well as the combination of both swabbing techniques. The RATs were performed sequentially in the same session and photographed. (B) An overview of the RAT's band intensity in relation to the control band for every week and for the three swabbing techniques.
case_images: fpubh-11-1240308-g002.jpg
case_images: PMC10657208_01_fpubh-11-1240308-g002.jpg
case_images: fig2
case_images: All four weekly RATs performed by oral swabbing were negative (Figure 2).
case_images: Serology results of serum sample provided prior to week 1. A blood sample was provided prior to performing the RATs, and serum was isolated. Antibodies against the SARS-CoV-2 (A) nucleocapsid and (B) Spike protein was performed using a previously established chemiluminescent ELISA serological assay. IgG antibodies were measured by titrating the subject's serum sample (red). In addition, a titration of a negative (blue) and positive (green) pooled serum from residual blood was included as positive and negative controls. Here the blank adjusted relative luminescence units (RLU) intensity is shown. IgG antibody titer against the nucleocapsid was below conversion threshold, IgG titer against the spike protein was estimated to be 130.41 BAU/mL.
case_images: fpubh-11-1240308-g003.jpg
case_images: PMC10657208_01_fpubh-11-1240308-g003.jpg
case_images: fig3
case_images: Only antibodies against the Spike protein were detected beyond our positivity threshold (Figure 3).